bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells.
about
Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancerA phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell linesSimultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis.Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cellsBufalin enhances the antitumor effect of gemcitabine in pancreatic cancerU1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In VivoEngineering RNA for targeted siRNA delivery and medical application.Challenges of drug resistance in the management of pancreatic cancer.Apoptosis-modulating drugs for improved cancer therapy.Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling.The role of apoptotic cell death in the radiosensitising effect of gemcitabine.pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
P2860
Q28534636-8A4185DB-C08E-4073-94A6-BB9EA4EF804BQ33415855-B93F0EB7-C176-474A-BD9F-FBD8BCD6328EQ33582958-1796AD55-9CB3-4F89-B4F9-F1EE79E6496EQ33636816-30A4389F-3301-4EB3-ABDF-3B60585383DCQ33719099-2237F3EB-2E1A-4C3A-8053-DD41EAEF7E8DQ34657372-AE884352-07CD-4B17-8261-57484EEDA8D3Q35194201-ED784F70-B857-4FCC-92DC-AD1FBA21D3F0Q35486194-30034A82-5BFE-48DC-80D9-1A8BC8447ED8Q36424040-4C38E652-8F3F-45EB-98F2-32DE6AD6A503Q36757152-C3767A3D-EDFA-4794-8CF7-E0E40AF51655Q37709610-715421F8-2A7B-43D4-B103-9C48888EABEEQ37799830-8C21E2F3-D911-495A-AC74-CA815D7A289EQ38005914-01D9A7B9-0B54-4C0D-BF7C-8551C19F7CFAQ39016327-4118A434-FEF8-4934-8B40-B79E170ED019Q39813658-D224847C-B7B8-496F-A1C8-0736A90285C4Q42113487-58BF0E4E-6A5A-49BB-961F-6F51E8449440
P2860
bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells.
@en
type
label
bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells.
@en
prefLabel
bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells.
@en
P2093
P2860
P1476
bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells.
@en
P2093
Christoph Herold
Daniel Neureiter
Eckhart G Hahn
Kinya Okamoto
Otto Dietze
Steffen Zopf
P2860
P304
P356
10.1111/J.1582-4934.2007.00013.X
P577
2007-03-22T00:00:00Z